Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback